These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24977978)

  • 1. Apolipoprotein A-I mimetics.
    Reddy ST; Navab M; Anantharamaiah GM; Fogelman AM
    Curr Opin Lipidol; 2014 Aug; 25(4):304-8. PubMed ID: 24977978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise of apolipoprotein A-I mimetics.
    Mendez AJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.
    Nayyar G; Mishra VK; Handattu SP; Palgunachari MN; Shin R; McPherson DT; Deivanayagam CCS; Garber DW; Segrest JP; Anantharamaiah GM
    J Lipid Res; 2012 May; 53(5):849-858. PubMed ID: 22377531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.
    Su F; Grijalva V; Navab K; Ganapathy E; Meriwether D; Imaizumi S; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
    Mol Cancer Ther; 2012 Jun; 11(6):1311-9. PubMed ID: 22416044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease.
    Valanti EK; Chroni A; Sanoudou D
    Curr Opin Lipidol; 2019 Aug; 30(4):326-341. PubMed ID: 31157629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux.
    Islam RM; Pourmousa M; Sviridov D; Gordon SM; Neufeld EB; Freeman LA; Perrin BS; Pastor RW; Remaley AT
    Sci Rep; 2018 Feb; 8(1):2956. PubMed ID: 29440748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.
    Anantharamaiah GM; Garber DW; White CR
    Protein Pept Lett; 2016; 23(11):1024-1031. PubMed ID: 27586181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.
    Wolska A; Reimund M; Sviridov DO; Amar MJ; Remaley AT
    Cells; 2021 Mar; 10(3):. PubMed ID: 33800446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties of apolipoprotein a-I mimetic peptides.
    Getz GS; Wool GD; Reardon CA
    Curr Atheroscler Rep; 2010 Mar; 12(2):96-104. PubMed ID: 20425244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structure/function of apoprotein A-I mimetic peptides: an update.
    Getz GS; Reardon CA
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):129-33. PubMed ID: 24569554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein mimetics in cancer.
    Delk SC; Chattopadhyay A; Escola-Gil JC; Fogelman AM; Reddy ST
    Semin Cancer Biol; 2021 Aug; 73():158-168. PubMed ID: 33188891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.
    Getz GS; Wool GD; Reardon CA
    Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of α-methylated amino acids into Apolipoprotein A-I mimetic peptides improves their helicity and cholesterol efflux potential.
    Islam R; Sviridov DO; Drake SK; Tunyi J; Abdoulaeva G; Freeman LA; Pastor RW; Remaley AT
    Biochem Biophys Res Commun; 2020 May; 526(2):349-354. PubMed ID: 32222278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.
    White CR; Garber DW; Anantharamaiah GM
    J Lipid Res; 2014 Oct; 55(10):2007-21. PubMed ID: 25157031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.
    Leman LJ; Maryanoff BE; Ghadiri MR
    J Med Chem; 2014 Mar; 57(6):2169-96. PubMed ID: 24168751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis.
    Sharifov OF; Xu X; Gaggar A; Grizzle WE; Mishra VK; Honavar J; Litovsky SH; Palgunachari MN; White CR; Anantharamaiah GM; Gupta H
    PLoS One; 2013; 8(5):e64486. PubMed ID: 23691230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.
    Ditiatkovski M; D'Souza W; Kesani R; Chin-Dusting J; de Haan JB; Remaley A; Sviridov D
    PLoS One; 2013; 8(7):e68802. PubMed ID: 23874769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
    Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
    Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.